Clinical Trial Information

APPROACH Open Label Study Fact Sheet (FCS)

BROADEN Study Fact Sheet (FPL)

More information about Akcea’s clinical trials is available at

Tools for Your Practice

Beyond the development of potential new treatments, Akcea is committed to supporting patients and health care professionals with informational resources.

For more information about FCS, please visit

As part of Akcea’s commitment to FCS education and the patient perspective please use these links to view expert presentations and patient interviews:

What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

Familial Chylomicronemia Syndrome: Cause, Effect, and Solutions to Improve Patients’ Quality of Life

hATTR Guide
hATTR Guide provides education and resources to empower healthcare professionals to diagnose, manage and better support their patients living with hATTR amyloidosis. To learn more about supporting hATTR amyloidosis patients, including identifying the red-flag symptoms; and diagnosing, managing, and treating the disease, visit or the hATTR Guide Twitter page.

hATTR Compass
Akcea and Ambry Genetics are partnering to offer no-cost confidential genetic testing and genetic counseling to patients suspected of having or clinically diagnosed with hATTR amyloidosis through the hATTR Compass Program. To learn more, visit

Additional resources, including a list of advocacy organizations, are available here.

Medical Congresses

Connect with the Akcea team at an upcoming medical meeting.

United States

American Academy of Neurology
Los Angeles, CA April 21-27

National Lipid Association
Indianapolis, IN, August 11-13

Endocrine Society Clinical Education Update
Chicago, IL, September 23-25

Cardiometabolic Health Congress
Boston, MA, October 4-7


British Cardiovascular Society
Manchester, England, June 5-7

Heart UK
Warwick, England, July 5-7

European Society of Cardiology
Barcelona, Spain, August 26-30

British Endocrine Society
Harrogate, England, November 6-8


International Society of Amyloidosis
Kumamoto, Japan, March 26-29


Akcea Therapeutics has been acquired by Ionis Pharmaceuticals. For continued news and information about Akcea Therapeutics, please visit You are being redirected, please wait. If you have not been redirected in 30 seconds, please click the button below.

Go to